BioWorld

March 8, 2002

View Archived Issues

Celgene Changing Course On Thalomid In Multiple Myeloma

Celgene Corp. is facing a delay in its new drug application for Thalomid after the FDA said it had to conduct a new trial in a different indication, but one that may be more lucrative over time. (BioWorld Today) Read More

Cubist Plans Cidecin NDA Filing This Year For Treating Infections

Read More

Besides Biting Fly, Parasitical Worm, River Blindness Needs Wolbachia Bacterial Infectivity

Read More

PDUFA Negotiations Likely To Lead To Increased Filing Fees

Read More

Other News To Note

Read More

Medicines Company Licenses Phase III Drug From AstraZeneca

Read More

U.S. Patent Disclosures

Read More